TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03622827

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy+ Endostar
Description: Chemoradiotherapy with Endostar：~* Chemoradiotherapy: pelvic radiotherapy starts 2-3 weeks after surgery. Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy. The external beam radiotherapy should be completed within 6 weeks.~* Concurrent chemotherapy is consisted of cisplatin (75 mg/m2, day 1-3) and 5-fluorouracil (5-FU; 1000mg/m2/day, civ, day 1-4) for 2 cycles every 3 weeks.~* Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the concurrent chemoradiotherapy for 2 cycles every 3 weeks.
Study: NCT04461470

Intervention type: GENETIC
Intervention: epigenetic longitudinal waves
Description: force - inducing energies using electromagnetic field(s)

Intervention type: GENETIC
Intervention: epigenetic longitudinal waves
Description: force - inducing energies using electromagnetic field(s)
Study: NCT04434144

Intervention type: DRUG
Intervention: Ivermectin + Doxycycline
Description: SARS-CoV-2 infection was confirmed by RT PCR in every case. For group A, Ivermectin 200mcg/kg single dose and Doxycycline 100mg BID for 10 days were given. For group B, Hydroxychloroquine 200mg BID for 10 days and Azithromycin 500mg single daily dose for 5days was given. Before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. Incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for PCR was done on 5th day. For the symptomatic patients, this duration was on the 3rd nonsymptomatic day from the first day of drug intake. In the case of positive PCR, the test was repeated after 2days and onward.

Intervention type: DRUG
Intervention: Hydroxychloroquine + Azithromycin
Description: SARS-CoV-2 infection was confirmed by RT PCR in every case. For group B, Hydroxychloroquine 400mg first day then 200mg BID + Azithromycin 500mg BID for 5 days were given. For group B, Hydroxychloroquine 200mg BID for 10 days and Azithromycin 500mg single daily dose for 5days was given. Before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. Incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for PCR was done on 5th day. For the symptomatic patients, this duration was on the 2nd nonsymptomatic day from the first day of drug intake. In the case of positive PCR, the test was repeated after 2days and onward.
Study: NCT01623271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Study: NCT00022529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-214662
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT05810220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrode-Neural Interface
Description: Measurements taken from the electrode-neural interface will be used to guide elimination of poorly functioning ABI electrodes and improve speech perception outcomes.
Study: NCT02025387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity feedback

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Usual care except physical activity measurement
Study: NCT04509466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase
Description: Drug: Liposomal mitoxantrone hydrochloride (12mg/m2, 16mg/m2, 20mg/m2, 24mg/m2) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase
Description: Drug: Liposomal mitoxantrone hydrochloride (RP2D defined in Part 1) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase
Description: Drug: Liposomal mitoxantrone hydrochloride (RP2D defined in Part 1) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle.
Study: NCT01097863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nelfilcon A contact lens, modified inversion indicator
Description: Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with modified inversion indicator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nelfilcon A contact lens, no inversion indicator
Description: Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with no inversion indicator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nelfilcon A contact lens, inversion indicator
Description: Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear, with inversion indicator
Study: NCT00293579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 IV every 3 weeks for 6 cycles
Study: NCT00257803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: See detailed description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: See detailed description
Study: NCT00352105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 20mg/m2/d IV continuous infusion x4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 1000mg.m2/d IV continuous x 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iressa
Description: 250mg/PO qd x 2 years

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hyperfractionated radiation therapy
Description: 120cGy bid
Study: NCT02577861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy from donor eye
Description: Corneal biopsy from undamaged limbus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant of Holoclar
Description: Implant of Holoclar into the eye to be treated after scraping of the fibrovascular pannus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ophtalmologic examination
Description: The following assessments are performed:~Epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; Best-Corrected Visual Acuity; ocular tonometry; slit lamp examination (both corneal endothelium and anterior chamber); conjunctival inflammation (both bulbar and limbal) assessment; corneal sensitivity and involvement assessment; Schirmer's test type I; evaluation of the following symptoms: pain, burning, photophobia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: Standard haematology, biochemistry and Infectious profile (Virology) are assessed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital pictures
Description: At least 4 digital corneal slit lamp photos without fluorescein and at least 4 digital corneal slit lamp photos with fluorescein are taken using digital camera

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECG
Description: A 12-lead ECG measurement in single recording at screening for safety reason and before each transplantation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Quality of Life assessment through the NEI VFQ 25and EQ-5D-3L questionnaire (EQ-5D-Y in paediatric population)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical examination and vital signs
Description: A complete physical examination and vital signs (Systolic and Diastolic Blood Pressure (SBP, DBP) and Pulse Rate (PR) must be assessed at each visit (but not at pre-screening and at visit 6)
Study: NCT02135718

Intervention type: DEVICE
Intervention: ELLIPTA inhaler
Description: ELLIPTA inhaler, placebo DPIwith 30 doses (2 strips with 30 blisters per strip containing lactose in strip first strip and Lactose blended with magnesium stearate in second strip)

Intervention type: DEVICE
Intervention: ELLIPTA inhaler
Description: ELLIPTA inhaler, placebo DPIwith 30 doses (2 strips with 30 blisters per strip containing lactose in strip first strip and Lactose blended with magnesium stearate in second strip)

Intervention type: DEVICE
Intervention: Placebo Inhalation Aerosol (MDI)
Description: Placebo inhaler MDI will be supplied containing aerosol propellant

Intervention type: DEVICE
Intervention: Placebo Inhalation Aerosol (MDI)
Description: Placebo inhaler MDI will be supplied containing aerosol propellant
Study: NCT02765360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Group
Description: Participants will be established on the randomised mode of ventilation and will have continuous assessment of the following during the assessment period:~* Electrical impedance tomography~* EMGpara~* SpO2~* tcCO2~* Pneumotachography~* End-tidal CO2 monitoring
Study: NCT01487915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GCb
Description: Gemcitabine 1000 mg/㎡ D1, D8 plus Carboplatin AUC=4.5 D1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GemOx
Description: Gemcitabine 1000 mg/㎡ D1 plus Oxaliplatin 100 mg/㎡ D1 every 2 weeks
Study: NCT01580397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INNO-206
Description: INNO-206 at a total dose of 350 mg/m2 (260 mg/m2 doxorubicin equivalent) will be administered as a 30 minute IV infusion every 21 days.
Study: NCT00941460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide in both arms
Description: initial dose 120 mg/m2 in arm A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide in both arms
Description: initial dose 80 mg/m2 in arm B
Study: NCT06314555

Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample to analyse the values of sFlt-1 and PlGF

Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample to analyse the values of sFlt-1 and PlGF

Intervention type: OTHER
Intervention: Vascular-renal sample
Description: Usual vascular-renal sample to analyse the values of sFlt-1 and PlGF

Intervention type: OTHER
Intervention: Vascular-renal sample
Description: Usual vascular-renal sample to analyse the values of sFlt-1 and PlGF
Study: NCT01732887

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive fitness training
Description: Computer-based training of basic cognitive functions. It has activities under two headings,~1. General training applications~2. Memory training applications~Each individual session in both groups will include playing specific computer games for at least 1/2 hour a day, 3 days per week, throughout the 10 week interval.

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive fitness training
Description: Computer-based training of basic cognitive functions. It has activities under two headings,~1. General training applications~2. Memory training applications~Each individual session in both groups will include playing specific computer games for at least 1/2 hour a day, 3 days per week, throughout the 10 week interval.
Study: NCT04074928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIVc
Description: Previously vaccinated subjects received a 0.5 mL intramuscular dose of QIVc on Day 1; not previously vaccinated subjects received a 0.5 mL intramuscular dose of QIVc on Day 1 and Day 29.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator QIV
Description: Previously vaccinated subjects received a dose of Comparator QIV on Day 1; not previously vaccinated subjects received a dose of Comparator QIV on Day 1 and Day 29. Subjects 6 months through 35 months of age received a 0.25 mL intramuscular dose of Comparator QIV; subjects 36 months through 47 months of age received a 0.5 mL intramuscular dose of Comparator QIV.
Study: NCT03447626

Intervention type: DEVICE
Intervention: MAKO Robotic UKA
Description: Prospective UKA patient receiving unilateral knee arthroplasty using the MAKO robotic machine
Study: NCT01627860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate add-on therapy
Description: Type=range, unit=mg/day, number=25-200, form=tablet, route=oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate monotherapy
Description: Type= range, unit= mg/day, number= 25-200, form= tablet, route= oral use.
Study: NCT00758745

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Model SN60WF
Description: Implantation with the AcrySof Model SN60WF Single-piece intraocular lens (IOL) following cataract removal.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Model MA60AC
Description: Implantation with the AcrySof Model MA60AC multi-piece intraocular lens (IOL) following cataract surgery.
Study: NCT02799069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BF-200 ALA
Description: topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL Cream
Description: topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: topical treatment for photodynamic therapy combining vehicle application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
Study: NCT02199197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium Ra 223 Dichloride
Description: Radium Ra 223 Dichloride, 55 kilobecquerel (kBq)/kg body weight, administered as a bolus intravenous (IV) injection (up to 1 minute) on Day 1 of each cycle for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide 160 mg administered orally once a day (continuously) for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide 160 mg administered orally once a day (continuously) for 6 cycles.
Study: NCT02551159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Anti-PD-L1 antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Anti-CTLA-4 Antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736+Tremelimumab

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Monoclonal Antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil (5FU)
Description: Chemotherapy Agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Chemotherapy agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Chemotherapy Agent
Study: NCT04218253

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 300 calories or 500 calories nutrient rich in branched chain amino acids and dietary fiber
Description: 300 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for Mild malnutrition, or 500 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for moderate to severe malnutrition. The degree of malnutrition is determined by Patient-Generated Subjective Global Assessment (PG-SGA).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dietary mission
Description: Dietary education was conducted according to preoperative nutritional requirements

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary mission
Description: Dietary education was conducted according to preoperative nutritional requirements
Study: NCT00640471

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: cetuximab (Erbitux®) - Initial dose - Day 1 (Week 1): 400 mg/m2 IV over 120 minutes Maintenance Infusions (subsequent weeks): 250 mg/m2 IV over 60 minutes

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: cetuximab (Erbitux®) - Initial dose - Day 1 (Week 1): 400 mg/m2 IV over 120 minutes Maintenance Infusions (subsequent weeks): 250 mg/m2 IV over 60 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brivanib alaninate
Description: brivanib (BMS-582664) 800 mg po, QD
Study: NCT00439582

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vaccenic acid enriched milk fat (VAMF) [Transfact1]

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: hydrogenated oil
Description: Partially hydrogenated vegetable oils (PHVO) and vegetable oils and fats
Study: NCT04643951

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview study using Grounded theory, to investigate dental professionals' and students' perception of child patient's experience and need for treatment regarding procedural and postoperative pain.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview study using Grounded theory, to investigate dental professionals' and students' perception of child patient's experience and need for treatment regarding procedural and postoperative pain.
Study: NCT00207051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib + Cetuximab
Description: Tablets/IV, Oral/IV , Brivanib 800 mg + Erbitux 400 mg/m2 X 1, followed by 250mg/m2, Brivanib QD / Erbitux QW, up to 48 weeks
Study: NCT03881995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IGlarLixi
Description: Dose titration will be done based on the subjects fasting blood glucose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine 100 UNT/ML
Description: Dose titration will be done based on the subjects fasting blood glucose
Study: NCT02555735

Intervention type: DRUG
Intervention: Standard of Care Chemotherapy
Description: Physician's Choice Chemotherapy Treatment (non-guided)
Study: NCT04145414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Reproductibility test assessed with MRI for cerebrospinal fluid movements
Study: NCT04116112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicardipine
Description: In the event where SBP values are above the randomly assigned target, intravenous nicardipine will be initiated at 2.5 mg/hr to lower the SBP. If SBP is still not reduced to below assigned target after 15 minutes, nicardipine dose will be increased by 2.5 mg/hr every 15 minutes until the target SBP or a maximum dose of 15 mg/hr is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicardipine
Description: In the event where SBP values are above the randomly assigned target, intravenous nicardipine will be initiated at 2.5 mg/hr to lower the SBP. If SBP is still not reduced to below assigned target after 15 minutes, nicardipine dose will be increased by 2.5 mg/hr every 15 minutes until the target SBP or a maximum dose of 15 mg/hr is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicardipine
Description: In the event where SBP values are above the randomly assigned target, intravenous nicardipine will be initiated at 2.5 mg/hr to lower the SBP. If SBP is still not reduced to below assigned target after 15 minutes, nicardipine dose will be increased by 2.5 mg/hr every 15 minutes until the target SBP or a maximum dose of 15 mg/hr is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetalol
Description: If SBP is above target despite maximum nicardipine infusion for 30 minutes, 10-20 mg of intravenous labetalol will be added every 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetalol
Description: If SBP is above target despite maximum nicardipine infusion for 30 minutes, 10-20 mg of intravenous labetalol will be added every 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetalol
Description: If SBP is above target despite maximum nicardipine infusion for 30 minutes, 10-20 mg of intravenous labetalol will be added every 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine
Description: If SBP remains unresponsive for 1 hr despite the use of maximum doses of nicardipine and labetalol, a Hydralazine will be added at the treating physician's discretion. Incidence of the latter scenario is anticipated to be exceedingly rare.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine
Description: If SBP remains unresponsive for 1 hr despite the use of maximum doses of nicardipine and labetalol, a Hydralazine will be added at the treating physician's discretion. Incidence of the latter scenario is anticipated to be exceedingly rare.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine
Description: If SBP remains unresponsive for 1 hr despite the use of maximum doses of nicardipine and labetalol, a Hydralazine will be added at the treating physician's discretion. Incidence of the latter scenario is anticipated to be exceedingly rare.
Study: NCT05541965

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reflexology and kegel exercises
Description: Reflexology is specific to a foot massage, and ıt can use different symptoms for patients.~Kegel exercise is specific an activities and ıt can used for urinary incontinence

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reflexology and kegel exercises
Description: Reflexology is specific to a foot massage, and ıt can use different symptoms for patients.~Kegel exercise is specific an activities and ıt can used for urinary incontinence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology and kegel exercises
Description: Reflexology is specific to a foot massage, and ıt can use different symptoms for patients.~Kegel exercise is specific an activities and ıt can used for urinary incontinence
Study: NCT04125355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: Foot reflexology massage for 3 consecutive days and 60 minutes per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 3 consecutive days and 60 minutes per day. This intervention only include touch to the foot, it doesn't include deep stimulation.
Study: NCT02695628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluoromisonidazole
Description: Undergo \[18F\] FMISO PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial Embolization
Description: Undergo transcatheter arterial embolization

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo \[18F\] FMISO PET/CT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo \[18F\] FMISO PET/CT